Open Label Study of Sildenafil in Patients With Pulmonary Arterial Hypertension
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
To assess the safety of sildenafil 20 mg TID orally given to Japanese pulmonary arterial
hypertension patients (Part 1 and 2) To assess the efficacy after 12 weeks of treatment of
sildenafil 20 mg TID orally given to Japanese pulmonary arterial hypertension patients (Part
1)
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.